Xenobiotics and Allergic Inflammation
异生素和过敏性炎症
基本信息
- 批准号:6663129
- 负责人:
- 金额:$ 144.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This UCLA Center proposal comprises four related research projects centered about the theme of the enhancement of airway, allergic inflammation by xenobiotic compounds generated from fossil fuel combustion. All projects address key issues regarding the pathways by investigators are original participants in this AAIDCRC. The fourth project brings on a new young investigator as Project Leader. The Projects examine clinical, cellular and molecular aspects of epithelial cells, macrophages, mast cells, basophils and lymphocytes all of which involved in allergic inflammation. In Project 1 (SAXON), the human in vivo challenge models developed in this enter will be used to test therapeutic approaches to inhibiting allergic in response to DEP and allergen. This will include the use of models of both primary sensitization and secondary boosting of allergic inflammation. "Proof of Principle:" approaches will be directed at i) anti-oxidants, ii) interrupting cytokine signaling (sIL-4R) and iii) deviation of the local immune response via CpG administration. In Project 2, (NEL) the role of oxidative stress in the generation of biological effects by DEP chemical will be studied by focusing on pro-inflammatory and anti-oxidant defense pathways. This will include the use of tissue culture macrophages and epithelial cells in vitro, as well as in vivo exposure of animals and humans to determine how a sensitive oxidant stress enzyme, heme oxygenase 1 (HO-1), protects against the pro-oxidative and pro-inflammatory effects of DEP. These studies will determine how modification of the HO-1 gene response pathway may predispose animals and humans to exaggerated allergic inflammatory responses. In Project 3 (HERSCHMAN), the mechanisms and consequences of DEP inhibition of prostaglandin products will be examined in cells, and in murine model of allergic airway inflammation and in human airway (PG) production will be examined genetically and pharmacologically in cells and in the animal challenge model. The basis for arachidonic acid sequestration in COX-1 vs. COX-2 PG synthesis will be elucidated, with a goal of utilizing this information to modulate immediate vs. delayed mast cell PGD2 production during inflammatory response. Difference in signaling pathways modulating COX-2 induction in mast cells vs. macrophages will be clarified, to provide cell-type specific approaches to pharmacologic modulation of PG production. Project 4 (Diaz-Sanchez) will determine the role of defined metabolic pathways for DEP xenobiotics and their relevant genes/gene products in mediating the allergic inflammatory responses to inhal4ed DEP in murine models of asthma. Advantage will also be taken of known functional human polymorphisms important oxidative stress pathways (GST and NQO1) to test whether they alter the responses to in vivo nasal DEP challenge. These studies identifying the pathways by which DEP, as a model xenobiotic, induce their effects on allergic inflammation will provide information in the other Center projects. The studies in this Center focus on xenobiotic modulation of mucosal allergic inflammation, using diesel exhaust particles as a relevant prototype. The project leaders comprise three senior investigators and one young investigator, each of whom has independent functioning but for whom the Center grant is the sole source of support for these studies on DEP. The projects are supported by a DEP collection and fractionation core, a mouse core, and a administrative, patient and sample coordination core.
加州大学洛杉矶分校的这项中心提案包括四个相关的研究项目,围绕着化石燃料燃烧产生的异物化合物增强呼吸道、过敏性炎症的主题。所有项目都解决了与路径有关的关键问题,调查人员是这一AAIDCRC的原始参与者。第四个项目引入了一位新的年轻调查员,担任项目负责人。这些项目检查了上皮细胞、巨噬细胞、肥大细胞、嗜碱性粒细胞和淋巴细胞的临床、细胞和分子方面,所有这些都与过敏性炎症有关。在项目1(撒克逊人)中,在这个项目中开发的人类活体挑战模型将被用于测试抑制对DEP和过敏原反应的过敏的治疗方法。这将包括使用过敏性炎症的初级致敏和次级强化模型。原则证明:方法将针对i)抗氧化剂,ii)阻断细胞因子信号转导(sIL-4R)和iii)通过给予CpG而偏离局部免疫反应。在项目2中,(NEL)将通过重点研究促炎和抗氧化防御途径来研究氧化应激在DEP化学物质产生生物效应中的作用。这将包括使用体外组织培养巨噬细胞和上皮细胞,以及动物和人类在体内的暴露,以确定一种敏感的氧化应激酶--血红素加氧酶1(HO-1)如何防止DEP的促氧化和促炎作用。这些研究将确定HO-1基因反应途径的修饰如何使动物和人类容易受到夸大的过敏性炎症反应的影响。在项目3(Herschman)中,将在细胞中检测DEP抑制前列腺素产物的机制和后果,在过敏性呼吸道炎症的小鼠模型中和在人类呼吸道(PG)的产生中,将在细胞和动物挑战模型中从遗传学和药理学的角度进行检测。花生四烯酸在COX-1和COX-2 PG合成中的基础将被阐明,目的是利用这一信息来调节炎症反应期间肥大细胞PGD2的即时和延迟产生。将阐明肥大细胞和巨噬细胞中调节COX-2诱导的信号通路的差异,为药物调节PG的产生提供细胞类型的特异性途径。项目4(Diaz-Sanchez)将确定DEP外源化合物及其相关基因/基因产物的特定代谢途径在介导吸入DEP引起的哮喘小鼠模型过敏性炎症反应中的作用。还将利用已知的人类重要氧化应激途径(GST和NQO1)的功能多态来测试它们是否会改变体内鼻部DEP挑战的反应。这些研究确定了DEP作为异种生物模型诱导其对过敏性炎症的影响的途径,这将在其他中心的项目中提供信息。该中心的研究以柴油机尾气微粒为相关原型,重点研究异源生物对粘膜变态反应性炎症的调节作用。项目负责人由三名高级调查员和一名年轻调查员组成,他们每个人都有独立的职能,但中心对他们的资助是对这些关于环境保护部的研究的唯一支持来源。这些项目得到了DEP收集和分级核心、鼠标核心以及行政、病人和样本协调核心的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW SAXON其他文献
ANDREW SAXON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW SAXON', 18)}}的其他基金
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
人类 Fc 双功能融合蛋白可治疗严重过敏性哮喘
- 批准号:
8057898 - 财政年份:2011
- 资助金额:
$ 144.46万 - 项目类别:
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
人类 Fc 双功能融合蛋白可治疗严重过敏性哮喘
- 批准号:
8249373 - 财政年份:2011
- 资助金额:
$ 144.46万 - 项目类别:
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
人类 Fc 双功能融合蛋白可治疗严重过敏性哮喘
- 批准号:
8523458 - 财政年份:2011
- 资助金额:
$ 144.46万 - 项目类别:
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
一种治疗猫过敏的治疗性 Fc gamma Fel d1 嵌合蛋白疫苗
- 批准号:
8307102 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
- 批准号:
8444422 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
猫过敏原-人Fc-gamma1嵌合蛋白治疗猫过敏
- 批准号:
7907314 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
一种治疗猫过敏的治疗性 Fc gamma Fel d1 嵌合蛋白疫苗
- 批准号:
8489254 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
Allergen???Fc-gamma1 proteins to treat food allergy
过敏原???Fc-gamma1蛋白治疗食物过敏
- 批准号:
7807490 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
用于治疗花生过敏的治疗性花生过敏原 Fc γ 嵌合蛋白
- 批准号:
8313432 - 财政年份:2010
- 资助金额:
$ 144.46万 - 项目类别:
Therapeutic anti-inflammatory phase II "anti-oxidant"
治疗性抗炎II期“抗氧化剂”
- 批准号:
7150197 - 财政年份:2006
- 资助金额:
$ 144.46万 - 项目类别:
相似海外基金
Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
- 批准号:
2901112 - 财政年份:2024
- 资助金额:
$ 144.46万 - 项目类别:
Studentship
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
- 批准号:
493135 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
- 批准号:
493526 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Operating Grants
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
- 批准号:
495593 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
- 批准号:
485504 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Salary Programs
Mechanistic Study of Inspiratory Training in Childhood Asthma
儿童哮喘吸气训练机制研究
- 批准号:
10637048 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
- 批准号:
10678307 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
- 批准号:
10664599 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 144.46万 - 项目类别: